Key result
Ab08 treatment resulted in 100% survival in SARS-CoV-2-infected hACE2 mice compared to 40% survival in the PBS control group.
Why the study?
Neutralizing antibodies are important tools against COVID-19, but most existing neutralizing antibodies lose activity against Omicron subvariants.
Does human monoclonal antibody Ab08 neutralize SARS-CoV-2 variants and provide therapeutic efficacy in infected mice?
Does human monoclonal antibody Ab08 neutralize SARS-CoV-2 variants and provide therapeutic efficacy in infected mice?
Ab08 is a human monoclonal antibody that neutralizes multiple SARS-CoV-2 variants, including Omicron subvariants, by destructing the Spike trimer, demonstrating therapeutic potential for COVID-19.
Answers are grounded in this paper and cite their sources.
Ab08 may template broad nAb design; leaves open clinical efficacy against evolving variants.
Neutralizing antibodies (nAbs) are important assets to fight COVID-19, but most existing nAbs lose the activities against Omicron subvariants. Here, we report a human monoclonal antibody (Ab08) isolated from a convalescent patient infected with the prototype strain (Wuhan-Hu-1). Ab08 binds to the receptor-binding domain (RBD) with pico-molar affinity (230 pM), effectively neutralizes SARS-CoV-2 and variants of concern (VOCs) including Alpha, Beta, Gamma, Mu, Omicron BA.1 and BA.2, and to a lesser extent for Delta and Omicron BA.4/BA.5 which bear the L452R mutation. Of medical importance, Ab08 shows therapeutic efficacy in SARS-CoV-2-infected hACE2 mice. X-ray crystallography of the Ab08-RBD complex reveals an antibody footprint largely in the β-strand core and away from the ACE2-binding motif. Negative staining electron-microscopy suggests a neutralizing mechanism through which Ab08 destructs the Spike trimer. Together, our work identifies a nAb with therapeutic potential for COVID-19.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2023) studied SARS-CoV-2 infection (n=10). Ab08 vs. PBS was evaluated on Survival at day 4 post-infection (p=<0.05). Ab08 treatment resulted in 100% survival in SARS-CoV-2-infected hACE2 mice compared to 40% survival in the PBS control group.
Synapse has enriched 10 related papers. Consider them for comparative context: